Last reviewed · How we verify

NCT04574752

MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing

Status unknown Last updated 5 October 2020
What this trial tests

trial testing next generation sequencing in Staphylococcus Aureus in 163 participants. Status unknown.

Timeline
30 August 2020
Primary endpoint
30 August 2021
30 August 2021

Quick facts

Lead sponsorRothman Institute Orthopaedics
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment163
Start date30 August 2020
Primary completion30 August 2021
Estimated completion30 August 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rothman Institute Orthopaedics

Who can join

Adults 18 to 80, any sex, with Staphylococcus Aureus or Next Generation Sequencing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this study were to evaluate the diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques and to model the potential effect of different diagnostic techniques on S. aureus detection in orthopaedic patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of next generation sequencing

Trials testing the same drug.

Other recruiting trials for Staphylococcus Aureus

Currently open trials in the same condition.

Other Rothman Institute Orthopaedics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04574752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing